 |
|
Gene panel predicts lung cancer survival, study finds
July 22, 2008Gene expression test could help determine who needs more aggressive treatment
ANN ARBOR, Mich. - Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment.
The study, the largest of its kind, appears online in Nature Medicine.
The researchers looked at 442 lung cancer tissue samples collected from six cancer hospitals in North America. They tested the cancer samples to look at the expression of hundreds of genes, and factored in clinical predictors such as tumor stage and the patients' gender and age. The results showed that the lung cancers could be divided into groups with better and worse survival rates.
Typically, lung cancer patients receive chemotherapy after surgery to reduce the risk of the cancer coming back. But specialists know that some patients with stage I disease, the earliest stage, have an aggressive disease with poor prognosis while some patients with more advanced stage II disease have a relatively good prognosis. The question is how to identify which patients need the additional therapy and which patients could potentially avoid it.
"We found that looking at clinical data along with gene expression can be a more reliable indicator. Gene expression is not just a black box approach - which a lot of researchers think it is. Sometimes knowing the context actually helps you use that information more efficiently," says study author David Beer, Ph.D., professor of surgery and radiation oncology at the University of Michigan Medical School and co-director of the Cancer Genetics Program at the U-M Comprehensive Cancer Center.
Lung cancer is particularly complex, with multiple types and subtypes, most of which are directly related to smoking. There are many genetic alterations induced by tobacco smoke exposure. To be able to offer one simple gene test for the disease, scientists would need to accurately model the known cellular diversity and the potential differences underlying the aggressiveness between lung cancers.
"Our findings suggest that there is a potential for successfully predicting lung cancer prognosis based on gene expression, but it is likely to be more difficult to develop a clinically useful test than has been suggested by previous studies. It's going to require more assay standardization and a large prospective study to identify a signature that is ready for clinical use," says study author Kerby Shedden, Ph.D., associate professor of statistics at U-M.
The researchers will continue to refine this process, identifying the important genes and testing them on tissue samples. They also plan in the future to test their predictors in a prospective trial, enrolling patients as they are diagnosed and following their progress. Enrollment for this trial has not begun.
Four institutions formed a consortium with support from the National Cancer Institute, to develop and validate gene expression signatures of lung cancers. The four institutions are the University of Michigan Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., Memorial Sloan-Kettering Cancer Center in New York, and Dana-Farber Cancer Institute in Boston.
Methodology: The researchers collected lung cancer tissue samples from six centers and grouped them into four sets based on the laboratories where the samples were processed. Two sets served as the "training set," in which researchers looked at several possible gene expression methods to determine whether they could be predictive of patient outcome. They then looked at the other two additional tumor sets for which all outcome data had remained unknown and blinded to the researchers, called "validation sets," to assess whether the outcome of the training set could be duplicated.
University of Michigan Health System
The researchers looked at 442 lung cancer tissue samples collected from six cancer hospitals in North America. They tested the cancer samples to look at the expression of hundreds of genes, and factored in clinical predictors such as tumor stage and the patients' gender and age. The results showed that the lung cancers could be divided into groups with better and worse survival rates.
Typically, lung cancer patients receive chemotherapy after surgery to reduce the risk of the cancer coming back. But specialists know that some patients with stage I disease, the earliest stage, have an aggressive disease with poor prognosis while some patients with more advanced stage II disease have a relatively good prognosis. The question is how to identify which patients need the additional therapy and which patients could potentially avoid it.
"We found that looking at clinical data along with gene expression can be a more reliable indicator. Gene expression is not just a black box approach - which a lot of researchers think it is. Sometimes knowing the context actually helps you use that information more efficiently," says study author David Beer, Ph.D., professor of surgery and radiation oncology at the University of Michigan Medical School and co-director of the Cancer Genetics Program at the U-M Comprehensive Cancer Center.
Lung cancer is particularly complex, with multiple types and subtypes, most of which are directly related to smoking. There are many genetic alterations induced by tobacco smoke exposure. To be able to offer one simple gene test for the disease, scientists would need to accurately model the known cellular diversity and the potential differences underlying the aggressiveness between lung cancers.
"Our findings suggest that there is a potential for successfully predicting lung cancer prognosis based on gene expression, but it is likely to be more difficult to develop a clinically useful test than has been suggested by previous studies. It's going to require more assay standardization and a large prospective study to identify a signature that is ready for clinical use," says study author Kerby Shedden, Ph.D., associate professor of statistics at U-M.
The researchers will continue to refine this process, identifying the important genes and testing them on tissue samples. They also plan in the future to test their predictors in a prospective trial, enrolling patients as they are diagnosed and following their progress. Enrollment for this trial has not begun.
Four institutions formed a consortium with support from the National Cancer Institute, to develop and validate gene expression signatures of lung cancers. The four institutions are the University of Michigan Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., Memorial Sloan-Kettering Cancer Center in New York, and Dana-Farber Cancer Institute in Boston.
Methodology: The researchers collected lung cancer tissue samples from six centers and grouped them into four sets based on the laboratories where the samples were processed. Two sets served as the "training set," in which researchers looked at several possible gene expression methods to determine whether they could be predictive of patient outcome. They then looked at the other two additional tumor sets for which all outcome data had remained unknown and blinded to the researchers, called "validation sets," to assess whether the outcome of the training set could be duplicated.
University of Michigan Health System
Lung Cancer Current Events and Lung Cancer News RSSRed wine may lower lung cancer risk
Moderate consumption of red wine may decrease the risk of lung cancer in men, according to a report in the October issue of Cancer Epidemiology, Biomarkers & Prevention¸ a journal of the American Association for Cancer Research.
Social class dictates cancer risk
Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy.
OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
Pazopanib shrinks lung cancers before surgery
Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report.
Joining forces against cancer
In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery.
Creating lung cancer risk models for specific populations refines prediction
Lung cancer risk prediction models are enhanced by taking into account risk factors by race and by measuring DNA repair capacity, according to research teams led by epidemiologists at The University of Texas M. D. Anderson Cancer Center in two complementary papers appearing in the September issue of Cancer Prevention Research.
African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease
Scientists at the M.D. Anderson Cancer Center have developed a risk prediction assessment for lung cancer specifically for African Americans that suggests a greater risk from chronic obstructive pulmonary disease (COPD).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Newly detected air pollutant mimics damaging effects of cigarette smoke
A previously unrecognized group of air pollutants could have effects remarkably similar to harmful substances found in tobacco smoke, Louisiana scientists are reporting in a study scheduled for presentation today at the 236th National Meeting of the American Chemical Society.
More Lung Cancer Current Events and Lung Cancer News Articles
 | Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke, Peggy McCarthy, Sarah Wernick Winner of the 2003 American Society of Journalists and Authors' June Roth Memorial Award for Health and Medical Books. An authoritative book with new lifesaving strategies for those at risk and those already diagnosed. Lung cancer kills more women than breast cancer, more men than prostate cancer—because it's usually found too late. Claudia Henschke's groundbreaking research on early... |
 | 100 Questions & Answers About Lung Cancer (100 Questions & Answers about . . .) by Karen Parles, Joan H. Schiller This book deals with lung cancer from a doctor's perspective and a patient's... |
 | How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer... |
 | Lung Cancer: A Guide to Diagnosis and Treatment by Walter Scott Are You Receiving the Best Treatment for Lung Cancer? If you’ve been diagnosed with lung cancer, you’re probably frightened. And, you probably have many questions. You’re wondering about prognosis and treatment. What will the treatments be like? Will you have side effects? But…are you asking whether or not you’re receiving the best treatment possible? According to Walter Scott, M.D.,... |
 | Lung Cancer: Making Sense of Diagnosis, Treatment, and Options by Lorraine Johnston Lung cancer is the number one cancer killer in the U.S., with over 170,000 new cases diagnosed each year. Despite this, it receives little attention from the media and little sympathy from the public. Those with lung cancer suffer more blame and stigma than other cancer patients, even though 50 percent of them are former smokers or have never smoked. Treatments for lung cancer can significantly... |
 | Lung Cancer: The Facts (Oxford Medical Publications) by Chris Williams Lung cancer is primarily a disease of well-developed affluent countries. It is by far the most common cancer in men, and could become more prevalent in women than breast cancer. Yet, although it is common, preventable, and sometimes curable, very little information is available about it. In a clear, accessible style, this thoroughly updated revised edition provides the answers to the questions... |
 | Lung Cancer: Dana-Farber Cancer Institute Handbook (Dana-Farber Cancer Institute Handbooks) Written by highly eminent authors, Lung Cancer - a handbook in the Dana-Farber Cancer Institute series - is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed... |
 | Lung Cancer: Current And Emerging Trends in Detection And Treatment (Cancer and Modern Science) by Julie Walker |
 | A Lung Cancer: Principles and Practice Thoroughly revised and updated, this Third Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. This edition includes sixteen new chapters and has been reorganized for greater clinical emphasis. Coverage includes complete information on combined... |
 | Lung Cancer by Jack A. Roth, James D. Cox, Waun Ki Hong Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been... |
| © 2008 BrightSurf.com |